Catheter Precision Inc. Engages PCG Advisory to Broaden Investor Relations Strategy
Catheter Precision (NYSE American: VTAK) has engaged PCG Advisory to enhance its investor relations strategy and market communications. The company, which develops cardiac electrophysiology medical devices, aims to strengthen engagement with institutional and retail investors while increasing awareness of its LockeT and VIVO™ technologies.
These innovative devices address challenges in electrophysiology and vascular closure, focusing on improving procedural efficiency and reducing complications. The company is entering its commercial phase, with CEO David Jenkins highlighting the potential of their technologies to deliver value to shareholders and healthcare providers.
The engagement comes as the electrophysiology market is projected to reach $15.1 billion by 2028, driven by increasing demand for ventricular ablation treatments and vascular closure solutions.
Catheter Precision (NYSE American: VTAK) ha assunto PCG Advisory per migliorare la sua strategia di relazioni con gli investitori e le comunicazioni di mercato. L'azienda, che sviluppa dispositivi medici per l'elettrofisiologia cardiaca, mira a rafforzare l'impegno con investitori istituzionali e al dettaglio, aumentando la consapevolezza delle sue tecnologie LockeT e VIVO™.
Questi dispositivi innovativi affrontano le sfide nell'elettrofisiologia e nella chiusura vascolare, concentrandosi sul miglioramento dell'efficienza procedurale e sulla riduzione delle complicazioni. L'azienda sta entrando nella sua fase commerciale, con il CEO David Jenkins che sottolinea il potenziale delle loro tecnologie nel fornire valore agli azionisti e ai fornitori di servizi sanitari.
Questo impegno arriva in un momento in cui si prevede che il mercato dell'elettrofisiologia raggiunga $15,1 miliardi entro il 2028, spinto dalla crescente domanda di trattamenti di ablazione ventricolare e soluzioni per la chiusura vascolare.
Catheter Precision (NYSE American: VTAK) ha contratado a PCG Advisory para mejorar su estrategia de relaciones con los inversores y las comunicaciones de mercado. La empresa, que desarrolla dispositivos médicos de electrofisiología cardíaca, busca fortalecer la participación con inversores institucionales y minoristas, al tiempo que aumenta la conciencia sobre sus tecnologías LockeT y VIVO™.
Estos dispositivos innovadores abordan los desafíos en la electrofisiología y el cierre vascular, centrándose en mejorar la eficiencia del procedimiento y reducir las complicaciones. La compañía está entrando en su fase comercial, con el CEO David Jenkins destacando el potencial de sus tecnologías para generar valor a los accionistas y proveedores de atención médica.
Este compromiso se produce en un momento en que se proyecta que el mercado de electrofisiología alcance $15.1 mil millones para 2028, impulsado por la creciente demanda de tratamientos de ablación ventricular y soluciones de cierre vascular.
Catheter Precision (NYSE American: VTAK)는 PCG Advisory를 고용하여 투자자 관계 전략과 시장 커뮤니케이션을 강화하고 있습니다. 심장 전기생리학 의료기기를 개발하는 이 회사는 기관 투자자 및 소액 투자자들과의 관계를 강화하고, LockeT 및 VIVO™ 기술에 대한 인식을 높이는 것을 목표로 하고 있습니다.
이 혁신적인 장치는 전기 생리학 및 혈관 폐쇄와 관련된 도전을 해결하며, 절차 효율성을 개선하고 합병증을 줄이는 데 중점을 두고 있습니다. 이 회사는 상업적 단계에 진입하고 있으며, CEO 데이비드 젠킨스는 그들의 기술이 주주 및 의료 제공자에게 가치를 전달할 잠재력을 강조하고 있습니다.
이 참여는 전기 생리학 시장이 2028년까지 151억 달러에 이를 것으로 예상되는 가운데 이루어지며, 이는 심실 절제술 치료와 혈관 폐쇄 솔루션에 대한 수요 증가에 의해 촉진되고 있습니다.
Catheter Precision (NYSE American: VTAK) a engagé PCG Advisory pour améliorer sa stratégie de relations investisseurs et ses communications sur le marché. L'entreprise, qui développe des dispositifs médicaux en électrophysiologie cardiaque, vise à renforcer l'engagement avec les investisseurs institutionnels et particuliers tout en augmentant la notoriété de ses technologies LockeT et VIVO™.
Ces dispositifs innovants répondent aux défis de l'électrophysiologie et de la fermeture vasculaire, en se concentrant sur l'amélioration de l'efficacité des procédures et la réduction des complications. L'entreprise entre dans sa phase commerciale, avec le PDG David Jenkins soulignant le potentiel de leurs technologies à offrir de la valeur aux actionnaires et aux prestataires de soins de santé.
Cette collaboration intervient alors que le marché de l'électrophysiologie devrait atteindre 15,1 milliards de dollars d'ici 2028, en raison de la demande croissante pour des traitements d'ablation ventriculaire et des solutions de fermeture vasculaire.
Catheter Precision (NYSE American: VTAK) hat PCG Advisory engagiert, um seine Strategie für die Investorenkommunikation und Marktkommunikation zu verbessern. Das Unternehmen, das medizinische Geräte für die kardiale Elektrophysiologie entwickelt, zielt darauf ab, die Interaktion mit institutionellen und privaten Investoren zu stärken und das Bewusstsein für seine Technologien LockeT und VIVO™ zu erhöhen.
Diese innovativen Geräte gehen Herausforderungen in der Elektrophysiologie und der vaskulären Verschlussbehandlung an, wobei der Fokus auf der Verbesserung der Verfahrenseffizienz und der Verringerung von Komplikationen liegt. Das Unternehmen tritt in seine kommerzielle Phase ein, wobei CEO David Jenkins das Potenzial ihrer Technologien betont, um den Aktionären und Gesundheitsdienstleistern Wert zu bieten.
Das Engagement erfolgt zu einem Zeitpunkt, an dem der Elektrophysiologiemarkt voraussichtlich bis 2028 15,1 Milliarden US-Dollar erreichen wird, angetrieben durch die steigende Nachfrage nach ventrikulären Ablationstherapien und vaskulären Verschlusslösungen.
- Company entering commercial phase with two innovative medical devices
- Operating in electrophysiology market projected to reach $15.1B by 2028
- Strategic expansion of investor relations through established advisory firm
- None.
BRIDGEWATER, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Catheter Precision Inc. (NYSE American: VTAK) (“Catheter Precision” or the “Company”), a U.S.-based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market, today announced its engagement with PCG Advisory, a leading investor relations, strategic communications, and digital strategies firm, to enhance investor outreach and communication efforts.
By partnering with PCG Advisory, Catheter Precision seeks to strengthen its engagement with institutional and retail investors, effectively communicate its strategic vision, and increase market awareness of its LockeT and VIVO™ technologies—two innovative devices that address key challenges in electrophysiology and vascular closure.
David Jenkins, CEO of Catheter Precision, commented, “As we enter the commercial phase of our mission to deliver long-term value to both shareholders and the healthcare sector, we believe LockeT and VIVO have the potential to significantly improve procedural efficiency while reducing complications and enhancing patient care. These technologies are designed to streamline workflows and better meet the needs of patients, hospitals and physicians. With key milestones ahead, a strong investor relations strategy supported by PCG Advisory will further share our story as we expand our operations.”
Jeff Ramson, Founder and CEO of PCG Advisory, added, “With its proven leadership, solid sales infrastructure, and presence in the high-growth electrophysiology and vascular closure sectors, we are excited to introduce Catheter Precision to our network of investors and stakeholders. We look forward to supporting the company in broadening its investor engagement and ensuring its unique value proposition is clearly and consistently communicated to the market.”
The electrophysiology market is projected to reach
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products. For more information, visit www.catheterprecision.com
About PCG Advisory, Inc.
PCG Advisory is a leading investor relations firm dedicated to the delivery of top-tier strategic services that encompass investor relations, capital markets navigation, digital strategies and corporate communications for innovative and emerging companies from around the globe. PCG Advisory has extensive experience with life sciences, technology and other emerging growth companies.
PCG Advisory is part of PCG Holdings Inc., a holding company for a network of resources dedicated to the discovery and creation of value in the small and micro-cap equity market that was founded in 2008. All subsidiaries of PCG Holdings are geared toward helping investors identify value where it is not most obvious by facilitating a dynamic flow of information between its clients and the investment community. PCG Holdings operating subsidiaries also includes PCG Digital, which owns, partners with and/or licenses innovative aggregation, distribution and engagement platforms. PCG Digital reaches thousands of individuals, retail, and institutional investors and stakeholders through its proprietary and extensive distribution network as well as through the use of unique multimedia marketing and audience development techniques. For more information, please go to: www.pcgadvisory.com.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as "believe," "anticipate," "may," "might," "can," "could," "continue," "depends," "expect," "expand," "forecast," "intend," "predict," "plan," "rely," "should," "will," "may," "seek," or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company's expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption "Risk Factors" in the Company's Form 10-K filed with the SEC and available at www.sec.gov.
The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
Company Contacts:
David Jenkins
CEO
973-691-2000
info@catheterprecision.com
Missiaen Huck
COO
9736912000
mhuck@catheterprecision.com
Investor Relations:
Jeff Ramson
PCG Advisory
jramson@pcgadvisory.com
FAQ
What is the projected market size for electrophysiology by 2028 according to VTAK's announcement?
What are the two main technologies Catheter Precision (VTAK) is commercializing?
Why did Catheter Precision (VTAK) engage PCG Advisory in February 2025?
What is the primary market focus of Catheter Precision (VTAK)?
